<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316366</url>
  </required_header>
  <id_info>
    <org_study_id>IRB12-00295</org_study_id>
    <nct_id>NCT02316366</nct_id>
  </id_info>
  <brief_title>The Use of Warmed Saline in Vaso-occlusive Episodes</brief_title>
  <official_title>Clinical Impact of Warmed Intravenous Saline in Sickle Cell Patients With Vaso-Occlusive Episodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if warming the intravenous (IV) fluid given to
      patients with Sickle Cell Disease who are experiencing painful episodes known as
      Vaso-Occlusive Episodes; will decrease rates of hospital admission, decrease amounts of IV
      pain medications given, improve pain and improve global comfort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaso-occlusive crisis (VOC) is a common painful complication of Sickle Cell Disease and is
      the primary reason that these patients seek medical care in the acute care setting. This
      complication arises when blood vessels are obstructed by sickled red blood cells resulting in
      ischemic injury.

      The standard management of these painful episodes comprises the administration of opioid
      analgesics, the infusion of intravenous (IV) fluids at room temperature and rest. These
      episodes often last five to seven days and many patients require inpatient management for
      continued administration of intravenous analgesics.

      The public health impact of the disease is large as admissions frequently result in school or
      work absences and can be financially and emotionally taxing.

      It is well established that exposure to cold precipitates VOC. For this reason, management of
      the pain of VOC in some centers includes the use of warming blankets as an adjunct for pain
      relief. It is conceptually appealing to conjecture that warm fluids might have similar
      salutary effects on VOC. This conjecture is bolstered by the physiologic effect of
      temperature on vascular tone. Specifically, it is well established that cold temperatures
      cause vasoconstriction whereas warm temperatures cause vasodilation. We expect that warmed
      fluids will similarly induce vasodilation, improving blood flow to vaso-occluded ischemic
      areas.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Hospital Admission</measure>
    <time_frame>4 hours</time_frame>
    <description>After being treated for pain in the Emergency Department, the disposition of the patient (whether admitted to the hospital for further care or discharge to home) was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>4 hours</time_frame>
    <description>During the ED stay, patient's pain scores on the Wong-Baker FACES scale was recorded at 30 minute intervals until disposition decided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disposition</measure>
    <time_frame>4 hours</time_frame>
    <description>The amount of time spent in the ED was recorded for each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Narcotic Administered</measure>
    <time_frame>4 hours</time_frame>
    <description>The amount of opioid analgesic administered in the ED prior to disposition was recorded for each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Comfort</measure>
    <time_frame>4 hours</time_frame>
    <description>Upon disposition patients were asked to complete a survey which assessed their global comfort during the ED stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Sickle Cell Crisis</condition>
  <arm_group>
    <arm_group_label>Warm fluid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Room temperature Fluid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive intravenous saline at room temperature (22-24 degrees Celsius)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Astoflo Plus fluid warmer</intervention_name>
    <description>A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius</description>
    <arm_group_label>Warm fluid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vaso-occlusive Episode defined as a pain rating of 3 or above on the Wong-Baker FACES
             score in a child with an established diagnosis of sickle cell disease (SS, SC or S Î²
             Thalassemia)

          -  4-21 years of age

        Exclusion Criteria:

          -  fever (temperature greater than 38 degrees Celsius)

          -  inability to complete FACES pain scale

          -  evidence of acute chest syndrome clinically or radiographically

          -  deemed by attending physician to be so ill as to need immediate hospital admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee Quarrie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Childrens Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Raphael JL, Mei M, Mueller BU, Giordano T. High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2012 Apr;58(4):584-90. doi: 10.1002/pbc.23181. Epub 2011 May 16.</citation>
    <PMID>21584938</PMID>
  </reference>
  <reference>
    <citation>Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H, Alabdullatif A, Al Sayegh M, Al Zahrani H, Hegazi M, Al Mohamadi A, Alsulaiman A, Omer A, Al Kindi S, Tarawa A, Al Othman F, Qari M. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost. 2010 Aug;16(4):365-76. doi: 10.1177/1076029609352661. Epub 2010 Jun 7. Review.</citation>
    <PMID>20530056</PMID>
  </reference>
  <reference>
    <citation>Raphael JL, Kamdar A, Wang T, Liu H, Mahoney DH, Mueller BU. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatr Blood Cancer. 2008 Sep;51(3):398-401. doi: 10.1002/pbc.21537.</citation>
    <PMID>18300322</PMID>
  </reference>
  <reference>
    <citation>Raphael JL, Kamdar A, Beavers MB, Mahoney DH, Mueller BU. Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital. Pediatr Blood Cancer. 2008 Jul;51(1):82-5. doi: 10.1002/pbc.21483.</citation>
    <PMID>18383165</PMID>
  </reference>
  <reference>
    <citation>Field JJ, Knight-Perry JE, Debaun MR. Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines. Curr Opin Hematol. 2009 May;16(3):173-8. doi: 10.1097/MOH.0b013e328329e167. Review.</citation>
    <PMID>19295432</PMID>
  </reference>
  <reference>
    <citation>Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R. Opportunities to improve outcomes in sickle cell disease. Am Fam Physician. 2006 Jul 15;74(2):303-10. Review.</citation>
    <PMID>16883928</PMID>
  </reference>
  <reference>
    <citation>Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991 Jul 4;325(1):11-6.</citation>
    <PMID>1710777</PMID>
  </reference>
  <reference>
    <citation>Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin. 2009;33(1):1-16. doi: 10.1080/03630260802625709. Review.</citation>
    <PMID>19205968</PMID>
  </reference>
  <reference>
    <citation>Jaja SI, Gbadamosi TA, Kehinde MO, Gbenebitse S. The effect of warmth or/and vitamin E supplementation on forearm blood flow and forearm vascular resistance in sickle cell and non sickle cell anaemia subjects. Niger Postgrad Med J. 2003 Mar;10(1):6-12.</citation>
    <PMID>12717457</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2014</study_first_posted>
  <results_first_submitted>July 31, 2015</results_first_submitted>
  <results_first_submitted_qc>July 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2015</results_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Renee Quarrie</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Warm Fluid</title>
          <description>Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
Astoflo Plus fluid warmer: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius</description>
        </group>
        <group group_id="P2">
          <title>Room Temperature Fluid</title>
          <description>Patients receive intravenous saline at room temperature (22-24 degrees Celsius)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Warm Fluid</title>
          <description>Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
Astoflo Plus fluid warmer: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius</description>
        </group>
        <group group_id="B2">
          <title>Room Temperature Fluid</title>
          <description>Patients receive intravenous saline at room temperature (22-24 degrees Celsius)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="4.7"/>
                    <measurement group_id="B2" value="13.6" spread="5.6"/>
                    <measurement group_id="B3" value="14" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Hospital Admission</title>
        <description>After being treated for pain in the Emergency Department, the disposition of the patient (whether admitted to the hospital for further care or discharge to home) was recorded.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warm Fluid</title>
            <description>Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
Astoflo Plus fluid warmer: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius</description>
          </group>
          <group group_id="O2">
            <title>Room Temperature Fluid</title>
            <description>Patients receive intravenous saline at room temperature (22-24 degrees Celsius)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hospital Admission</title>
          <description>After being treated for pain in the Emergency Department, the disposition of the patient (whether admitted to the hospital for further care or discharge to home) was recorded.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="48" upper_limit="78"/>
                    <measurement group_id="O2" value="55" lower_limit="40" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score</title>
        <description>During the ED stay, patient's pain scores on the Wong-Baker FACES scale was recorded at 30 minute intervals until disposition decided.</description>
        <time_frame>4 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disposition</title>
        <description>The amount of time spent in the ED was recorded for each patient</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warm Fluid</title>
            <description>Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
Astoflo Plus fluid warmer: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius</description>
          </group>
          <group group_id="O2">
            <title>Room Temperature Fluid</title>
            <description>Patients receive intravenous saline at room temperature (22-24 degrees Celsius)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disposition</title>
          <description>The amount of time spent in the ED was recorded for each patient</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="140" upper_limit="175"/>
                    <measurement group_id="O2" value="155" lower_limit="135" upper_limit="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Narcotic Administered</title>
        <description>The amount of opioid analgesic administered in the ED prior to disposition was recorded for each patient</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warm Fluid</title>
            <description>Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
Astoflo Plus fluid warmer: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius</description>
          </group>
          <group group_id="O2">
            <title>Room Temperature Fluid</title>
            <description>Patients receive intravenous saline at room temperature (22-24 degrees Celsius)</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Narcotic Administered</title>
          <description>The amount of opioid analgesic administered in the ED prior to disposition was recorded for each patient</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.23" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.23" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Comfort</title>
        <description>Upon disposition patients were asked to complete a survey which assessed their global comfort during the ED stay</description>
        <time_frame>4 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Warm Fluid</title>
          <description>Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
Astoflo Plus fluid warmer: A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius</description>
        </group>
        <group group_id="E2">
          <title>Room Temperature Fluid</title>
          <description>Patients receive intravenous saline at room temperature (22-24 degrees Celsius)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Renee Quarrie, fellow</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>2037136871</phone>
      <email>reneepetagae@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

